Accord Healthcare Ltd v. Medac Gesellschaft für Klinische Spezialpräparate MBH, Disctrict Court The Hague, 27 July 2016, Case No. ECLI:NL:RBDHA:2016:8596

Medac’s patent is found to be invalid. According to the Court the objective technical problem to be overcome was the developing of a subcutaneously administrable formulation of MTX that reduces the pain caused by the injection of relatively large volumes.

The Court ruled that the skilled person ‘would’ come to the solution of increasing the concentration of MTX solution as claimed in the patent.

A copy of the judgment can be read here.